28 Oct 2022

We recently acted for Nucleome Therapeutics in their Series A funding, raising £37.5M to decode the dark matter of the human genome to deliver first-in-class precision medicines.

The round was led by M Ventures, the strategic, corporate venture capital arm of Merck KGaA, with participation from Oxford Science Enterprises Plc, Johnson & Johnson Innovation – JJDC Inc, British Patient Capital Limited, and Pfizer Ventures (US) LLC.

Nucleome Therapeutics Limited is a biotechnology company that has the unique ability to discover and validate first-in-class targets by decoding the ‘dark’ side of the human genome, that holds over 90% of disease-linked genetic variants, which has not been fully explored. Nucleome now has the ability to link these variants to genes and map disease pathways for drug discovery.

Nucleome Therapeutics has said they plan to use the funds raised to drive its autoimmune disease programs and assisting in their mission to decode the dark matter of the human genome.

Dr Danuta Jeziorska, Co-founder and CEO of Nucleome Therapeutics said “Nucleome’s pioneering genomics platform technology has the potential to fundamentally shift the way we discover and develop precision medicines. We are unlocking the value of genetics in the largely uncharted territory of the genome, called the dark genome, to discover and develop first-in-class therapeutics. Taylor Vinters’ team played an instrumental role during our recent Series A fundraise, from term sheet stage to completion. Their dedication, speed, responsiveness, invaluable expertise, and general support was pivotal in the process. People are at the heart of every business and Taylor Vinters’ team indeed is a testament to it.”

Nicola McConville, Partner in the Emerging Companies Team said: “We were delighted to work with Danuta and the team at Nucleome on the company’s Series A. We wish them every success on their quest to discover new medicines by decoding the human genome and are excited to be a part of their story”.

Our deal team that work within our wider Emerging Companies Team consisted of Nicola McConville (Partner), Nicola Sole (Managing Associate) and Alexa Hamilton (Associate).